DENVER — Researchers announced Monday they are recruiting potential study participants for another COVID-19 investigational vaccine clinical trial.
The trial, at the University of Colorado School of Medicine and UCHealth on the CU Anschutz Medical Campus, is the third COVID-19 vaccine trial underway at UCHealth locations.
>Video above: Colorado hospital systems get ready for mass vaccinations.
UCHealth said the investigational vaccine, NVX-CoV2373, which contains a protein antigen and the company’s Matrix-M adjuvant, is being evaluated in a phase 3 clinical trial sponsored by Novavax and supported by the National Institutes of Health.
Studies have already proven that when injected with the Novavax vaccine candidate, the body creates antibodies that theoretically could fight of the spike proteins of the COVID-19 virus.
"We don’t know if this vaccine protects against COVID illness, and that’s the purpose of the phase 3 study, is to evaluation a vaccine for efficacy," Dr. Thomas Campbell, UCHealth's Chief Clinical Research Officer, told 9NEWS.
The recruitment period will run about two months at UCHealth University of Colorado Hospital.
UCHealth and CU School of Medicine researchers will recruit study participants or the clinical trial, and participants will be monitored for two years to determine the vaccine’s safety and whether they contract COVID-19. Two thirds of the study participants will receive one dose of NVX-CoV2373 21 days apart; one third will receive a placebo.
"If someone enrolls in the trial, and two months from now, they are offered an appointment to get a vaccine [that has already received emergency use approval], we can un-blind them, let them know what they got in the trial so they can go on and get the vaccine if they still need it," according to Dr. Campbell.
UCHealth said the emphasis of the Novavax phase 3 trial is on demonstrating safety and effectiveness of the vaccine in people who are most at-risk for contracting and becoming ill from COVID-19.
Study participants from throughout Colorado will be invited to participate, though they will have to travel to the Anschutz Medical Campus for their appointments.
Potential participants will be contacted through UCHealth’s My Health Connection patient portal and invited to participate if they meet the criteria for the trial. Anyone who is interested in participating can also send an email to firstname.lastname@example.org.
“This pivotal phase 3 clinical trial in the U.S. and Mexico is critical to building on the encouraging safety and immunogenicity data we’ve generated to-date and ultimately demonstrating how well NVX-CoV2373 works to prevent COVID-19,” said Gregory M. Glenn, MD, President of R&D, Novavax. “We are grateful to the thousands of volunteers who are stepping forward to participate in this vital research.”
“University of Colorado Hospital is part of the nationwide network called the COVID-19 Prevention Network, which has sites that are available to enroll into multiple sequential vaccine studies,” said Dr. Campbell.
UCHealth is also participating in the AstraZeneca COVID-19 vaccine trial in northern Colorado, and the Moderna COVID-19 vaccine trial wrapped up at University of Colorado Hospital at the end of October after enrolling more than 180 study participants.
“Identifying, inviting and enrolling study participants in trials like this takes a significant amount of work, and the Clinical and Translational Research Center (CTRC) research nurses and scheduling staff should be commended for their work along with UCHealth’s IT and My Health Connection teams who have used our electronic medical record in innovative ways to invite study participants to participate in the trial,” said Dr. Jean Kutner, chief medical officer of University of Colorado Hospital.
“CU’s world-class researchers have long excelled at bringing the latest clinical trials to our campus and we’ll continue to do that with COVID-19 vaccines and treatments,” said Donald M. Elliman Jr., chancellor of the CU Anschutz Medical Campus. “Today’s announcement is further evidence of how we continue to make strides with important research that showcases our strength as a leading academic medical campus.”
> Top stories curated daily just for you! Sign up for the 9NEWSLETTER to get can’t-miss stories, Next and Broncos content, weather and more delivered right to your inbox.
SUGGESTED VIDEOS: COVID-19 Coronavirus
MORE WAYS TO GET 9NEWS
Subscribe to our daily 9NEWSLETTER
HOW TO ADD THE 9NEWS APP TO YOUR STREAMING DEVICE
ROKU: add the channel from the ROKU store or by searching for KUSA.
For both Apple TV and Fire TV, search for "9news" to find the free app to add to your account. Another option for Fire TV is to have the app delivered directly to your Fire TV through Amazon.